Optiscan Imaging Says 84 Cases Imaged in Study Using Digital Pathology Imaging Device

MT Newswires Live
昨天

Optiscan Imaging (ASX:OIL) said 84 cases were imaged in its digital pathology study with Australian Clinical Labs (ASX:ACL), using its InForm digital pathology imaging device, according to a Thursday Australian bourse filing.

The device is providing real-time, slide-free cellular imaging at the point of contact. The cases imaged to date span a broad range of human tissue samples across multiple organs and systems as well as pathologies.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10